28 January 2020

ASX Announcement

Clarification Announcement

28 January 2020 – Race Oncology Limited (ASX: RAC) advises that further to this morning's announcement regarding the appointment of Professor Borje Andersson as a Non-Executive Director, the Company wishes to clarify that the effective date of the commencement of Professor Andersson's appointment is 1 February 2020.

- **ENDS** -

About Race Oncology (RAC: ASX)

Race Oncology is a specialty pharmaceutical Company whose business model is to pursue later-stage drugs in the cancer field that have been overlooked by big pharma. The Company's first drug is Bisantrene, a chemotherapy agent that was the subject of more than 40 clinical studies during the 1980s and 1990s before the drug was abandoned. Bisantrene has compelling clinical data in acute myeloid leukaemia (AML) as well as other cancers including breast and ovarian. Race is seeking to gain US FDA approval for Bisantrene and is pursuing a '5-Path' clinical development strategy that involves US and Australian clinical trials. Bisantrene is the subject of three recently granted US patents owned by Race and has been awarded US Orphan Drug designation and a 'Rare Paediatric Disease' (RPD) designation that entitles Race to a valuable Priority Review Voucher (PRV) upon approval.

About Professor Borje Andersson

Borje S. Andersson is Professor, Department of Stem Cell Transplantation in the Division of Cancer Medicine at University of Texas MD Anderson Cancer Center in Houston, Texas and Director of the Department's program for Molecular Pharmacology and Translational Drug Development. He is also Adjunct Professor, University of Houston College of Pharmacy in Houston. He received his medical degree from Karolinska Institute Faculty of Medicine and is board-certified in medical oncology, internal medicine and haematology. He has been an active researcher in the leukaemia field and his recent research has focused on the development of less toxic and more efficacious pre-transplant conditioning therapies, and improving the understanding of leukaemic cell resistance to bifunctional DNA-alkylating agents.

Release authorised by:

Peter Molloy, Managing Director

plmolloy@raceoncology.com

Media contact:

Heidi Cuthbert

+61 411 272 366

heidi.cuthbert@multiplier.com.au